Differentiation of LGM-1 Cells Transfected With Full-Length or Mutant G-CSFR Expression Plasmids as Determined by FcγII/III Receptor Expression After G-CSF Treatment
| Cell Line . | FcγII/III Receptor Expression7-150 (relative fluorescence intensity) . |
|---|---|
| LGM V | 0.97 |
| LGM GR95 | 2.05 |
| LGM GR-A | 1.70 |
| LGM GR-B | 1.78 |
| LGM GR-C | 2.15 |
| LGM GR-D | 0.92 |
| LGM GR-E | 0.99 |
| LGM GR-F | 0.95 |
| Cell Line . | FcγII/III Receptor Expression7-150 (relative fluorescence intensity) . |
|---|---|
| LGM V | 0.97 |
| LGM GR95 | 2.05 |
| LGM GR-A | 1.70 |
| LGM GR-B | 1.78 |
| LGM GR-C | 2.15 |
| LGM GR-D | 0.92 |
| LGM GR-E | 0.99 |
| LGM GR-F | 0.95 |
Transfected cells were treated for 10 days with 10 ng/mL of rhG-CSF.
Transfected cells were stained with fluorescein isothiocyanate-conjugated rat anti-mouse FcγII/III receptor MoAb. The fluorescence intensity of untreated cells was defined as 1.00, and the numbers represent the fold change in fluorescence intensity compared with untreated cells. (The expression of FcγII/III receptor was measured every 3 days for a period of 10 days or more, and the differentiation capacities of each of the transfected cell lines showed the same pattern of differentiation from day to day. The relative fluorescence intensity values indicated in the table are representative of the FcγII/III receptor expression observed on day 10.)